Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Seo, Yu Bin | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Cho, Geum Joo | - |
dc.contributor.author | Hwang, Taik Gun | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.accessioned | 2021-09-05T21:59:53Z | - |
dc.date.available | 2021-09-05T21:59:53Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/102227 | - |
dc.description.abstract | Elderly people are at great risk for influenza-related serious complications. However, influenza vaccine-induced antibodies are believed to decline more rapidly in the elderly. This study was designed to evaluate the long-term and cross-reactive immunogenicity among those aged 65 years for two seasonal trivalent influenza vaccines during the 2009-2010 influenza season. One vaccine had the MF59 adjuvant, while the other did not contain an adjuvant. Serum hemagglutinin inhibition (HI) titers were determined pre-vaccination and at 1 and 6 months post-vaccination. Of the 100 subjects, 95 (95%) were followed-up for 1 month after vaccination, and 76 (76%) were followed-up for 6 months after vaccination. Both vaccines met the European Medicines Agency (EMA) criteria 1 month after vaccination. However, seroprotection for influenza B was not satisfactory, with a rate of 55.3% for the MF59 adjuvant vaccine and 47.9% for the vaccine without adjuvant. At 6 months post-vaccination, the MF59-adjuvanted vaccine showed a higher seroprotection rate than the unadjuvanted vaccine. At this point, the MF59-adjuvanated vaccine still met the criteria of EMA for A/H1N1 (62.5% vs. 55.5%, P=0.64) and A/H3N2 (72.5% vs. 47.2%, P=0.04). Both vaccines showed excellent cross-reactive immunogenicity for influenza A/Solomon Island/3/2006 (H1N1) and A/Wisconsin/67/2005 (H3N2), without significant differences. In comparison, cross-reactive immunogenicity was not remarkable for the A/California/7/2009 (H1N1) and A/New Caledonia/20/1999 (H1N1) strains, which have a greater antigenic distance. In conclusion, the MF59-adjuvanted influenza vaccine showed superior long-term immunogenicity in the elderly compared to the unadjuvanted vaccine. However, cross-reactive immunogenicity was not remarkably enhanced with the MF59 adjuvant. J. Med. Virol. 85:1591-1597, 2013. (c) 2013 Wiley Periodicals, Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | VIRUS | - |
dc.subject | SUBUNIT | - |
dc.subject | PROTECTION | - |
dc.subject | SEASONS | - |
dc.subject | SAFETY | - |
dc.subject | STRAIN | - |
dc.title | Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Joon Young | - |
dc.contributor.affiliatedAuthor | Cheong, Hee Jin | - |
dc.contributor.affiliatedAuthor | Noh, Ji Yun | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.contributor.affiliatedAuthor | Kim, Woo Joo | - |
dc.identifier.doi | 10.1002/jmv.23630 | - |
dc.identifier.scopusid | 2-s2.0-84880357009 | - |
dc.identifier.wosid | 000321699700014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MEDICAL VIROLOGY, v.85, no.9, pp.1591 - 1597 | - |
dc.relation.isPartOf | JOURNAL OF MEDICAL VIROLOGY | - |
dc.citation.title | JOURNAL OF MEDICAL VIROLOGY | - |
dc.citation.volume | 85 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1591 | - |
dc.citation.endPage | 1597 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | SUBUNIT | - |
dc.subject.keywordPlus | PROTECTION | - |
dc.subject.keywordPlus | SEASONS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | STRAIN | - |
dc.subject.keywordAuthor | immunogenicity | - |
dc.subject.keywordAuthor | influenza vaccine | - |
dc.subject.keywordAuthor | elderly | - |
dc.subject.keywordAuthor | MF59 adjuvant | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.